The contract biomanufacturing global market is expected to grow at double digit CAGR to reach $36.6 billion by 2025
The biomanufacturing industry requires adequate capital as well as sufficient technical expertise. Bio-manufacturing refers to the manufacturing of the biologic molecules that are used in the different stages of drug development, starting from the pre-clinical stage to the commercial supply stage. To give more focus on core competencies and reduce the heavy capital investments, many pharmaceutical companies are outsourcing the drug manufacturing process.
The contract biomanufacturing services are helpful for efficient manufacturing of drugs at a lower cost. The application of single-use bioreactors is further bringing down the manufacture facility cost. The small pharma companies to meet their manufacturing needs can outsource their requirements to the contract biomanufacturing services instead of constructing fixed stainless steel bioreactor-based bioprocessing systems.
Key Market Drivers and Barriers
The key market drivers of the global contract biomanufacturing services are increased fundings from the government organizations as well as private venture capitals, globalization of bio-manufacturing facilities, technological advancements, and increasing budget of outsourcing.
Some of the key barriers of the global market growth are stringent regulations, restriction of outsourcing only to small and mid-sized companies, mandatory cGMP certifications, and the unequal bio-manufacturing capacities distribution worldwide.
Key Market Players
Some of the leading global market players of contract biomanufacturing services are Lonza, Catalent, Boehringer Ingelheim, and Samsung Biologics.
Other significant players in the global market include Fujifilm Diosynth, Wuxi, JSR Corporation, Rentschler Biotechnologies GmbH, Thermo Fisher, Charles River, Albany Molecular, Merck KGaA, Innovent Biologics, and Abbvie Contract Manufacturing.
Important Market Segmentation
The global contract biomanufacturing services market is segmented based on service, product, and region.
Based on the service, the global market is divided into process development, analytical and QC studies, packaging, and fill and finish operations. The process development is further segmented into downstream and upstream. The process development services are the leading segment in the global market.
Based on the product, the global market includes biologics and biosimilars. The biologics segment is further subdivided into vaccines, monoclonal antibodies, antisense, RNAi, and molecular therapy, and recombinant proteins.
Regional Market Outlook
The regional segmentation of the global contract biomanufacturing services market includes the North America region, Asia Pacific region, Latin America region, Europe region, the Middle East and Africa region, and others. The North America region is the market leader of contract biomanufacturing services across the globe. The growing opportunity of biologic outsourcing is expected to expand the market of the Asia Pacific region. India and China are the major contributors to market growth in the Asia Pacific region. The favourable government regulations, high technical expertise, and lower labour cost fuels the market growth in the region. The Asia Pacific region is anticipated to witness further market growth during the forecast period.
Latest Industry News
In September 2019, Lonza and Celltrion have signed a contract manufacturing agreement for producing drug substance for Remsima for autoimmune diseases including rheumatoid arthritis and Crohn’s disease.
In August 2019, Alvotech and Prestige Biopharma entered into a contract manufacturing collaboration marking an important milestone towards the expansion of contract manufacturing business.
For further information on this report, visit – https://www.wiseguyreports.com/reports/1793689-contract-biomanufacturing-services-global-market-forecast-to-2025
Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)